---
title: "减肥药物市场全球报告 2025-2035：医学研究的进步已经导致开发出更有效且更安全的减肥药物，并且负面副作用更少"
description: "全球减肥药市场预计将在 2025 年至 2035 年间显著增长，主要受肥胖率上升和医学研究进展的推动，这些进展导致了更安全、更有效的药物问世。像 semaglutide 和 liraglutide 这样的处方药因其临床疗效而日益受到欢迎，但对副作用和高成本的担忧可能会阻碍市场增长。北美预计将主导市场，得益于强大的医疗保健系统和高肥胖率。主要参与者包括诺和诺德、礼来和辉瑞"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/233478728.md"
published_at: "2025-03-27T14:26:32.000Z"
---

# 减肥药物市场全球报告 2025-2035：医学研究的进步已经导致开发出更有效且更安全的减肥药物，并且负面副作用更少

> 全球减肥药市场预计将在 2025 年至 2035 年间显著增长，主要受肥胖率上升和医学研究进展的推动，这些进展导致了更安全、更有效的药物问世。像 semaglutide 和 liraglutide 这样的处方药因其临床疗效而日益受到欢迎，但对副作用和高成本的担忧可能会阻碍市场增长。北美预计将主导市场，得益于强大的医疗保健系统和高肥胖率。主要参与者包括诺和诺德、礼来和辉瑞

Dublin, March 27, 2025 (GLOBE NEWSWIRE) -- The "Weight Loss Drugs Market - A Global and Regional Analysis: Focus on Type, Mechanism of Action, Route of Administration, Distribution Channel, and Country-Level Analysis - Analysis and Forecast, 2025-2035" report has been added to **ResearchAndMarkets.com's** offering.

The weight loss drugs market has experienced significant growth in recent years, largely driven by the increasing global prevalence of obesity and related health conditions. As more individuals seek effective and convenient solutions for managing their weight, the pharmaceutical industry has responded by offering a variety of drug options designed to aid in weight loss or help maintain a healthy weight.

According to the World Health Organization (WHO), over 2 billion people worldwide were classified as overweight or obese in 2021. This growing health concern has made weight loss drugs an attractive solution for individuals who struggle to lose weight through traditional methods such as diet and exercise. Additionally, obesity is linked to several chronic diseases, including type 2 diabetes, cardiovascular diseases, and certain cancers, further driving the demand for effective weight loss treatments.

Furthermore, advances in medical research have led to the development of more effective and safer weight loss medications, thereby driving the market growth. For instance, semaglutide (Wegovy) has shown promise in clinical trials, with patients losing up to 15% of their body weight after a year of treatment. This has created a wave of interest in prescription medications that go beyond the limitations of traditional diet pills. Also, the emergence of injectable drugs such as Wegovy and Saxenda has provided alternative options for individuals who cannot rely on oral medications. This is expected to impel the market growth over a forecast period.

However, side effects and safety concerns related to weight loss drugs are expected to limit the adoption and hinder market growth. Some medications such as orlistat can lead to gastrointestinal issues, while others may cause mood swings or increase the risk of heart-related problems. Consumers are often cautious about taking medications that come with potential long-term health risks. Even newer drugs like semaglutide, which show promising results, can lead to side effects such as nausea, vomiting, and diarrhea, which may deter individuals from continued use.

In addition, the high cost of prescription weight loss medications can be a major barrier to access, especially in countries with less favorable insurance coverage or where individuals do not have the financial means to afford treatment.

Key players in the market are Eli Lilly & Co, Pfizer Inc., F. Hoffmann-La Roche, GlaxoSmithKline (GSK), Sun Pharma, Amgen Inc., Rhythm Pharmaceuticals, Currax Holdings USA LLC, Boehringer Ingelheim, Vivus Inc., Gelesis, and Novo Nordisk

**Prescription Weightloss Drug to Lead the Weight Loss Drug Market**

Prescription weight loss drugs dominate the market over OTC alternatives due to their superior efficacy, strong clinical validation, and the ability to be closely monitored by healthcare providers. Medications like Wegovy (semaglutide) and Saxenda (liraglutide) have demonstrated significant weight loss results in clinical trials, targeting key metabolic pathways such as appetite control and fat metabolism. These FDA-approved drugs are often prescribed to individuals with obesity or related comorbidities, providing a personalized, evidence-based treatment approach.

In contrast, OTC options such as Alli (orlistat) offer limited effectiveness and lack the rigorous regulatory oversight and clinical backing that prescription drugs benefit from. The success of prescription drugs like Ozempic, initially developed for diabetes, further solidifies their dominance, as they provide weight loss of up to 20% of body weight, which is a more attractive and reliable proposition compared to the modest results typically associated with OTC products.

**North America Region to Lead the Weight Loss Market**

North America is dominating the weight loss drug market due to a combination of high obesity rates, strong healthcare infrastructure, and significant investment in pharmaceutical innovation. In the U.S., nearly 42% of adults are obese, according to the CDC, which drives a growing demand for weight loss solutions. Pharmaceutical companies have capitalized on this demand, with drugs such as Wegovy and Ozempic gaining massive popularity.

These medications, originally developed for diabetes, have shown remarkable success in promoting weight loss and are now marketed as primary solutions for obesity. The U.S. also has one of the highest rates of medical prescriptions for weight management, supported by insurance reimbursements and widespread access to healthcare. This has created a favorable environment for companies to aggressively market these treatments, thus maintaining North America's lead in the global weight loss drug market.

**Weight Loss Drugs Market Competitive Landscape**

-   Novo Nordisk
-   Eli Lilly & Co
-   Pfizer Inc.
-   F. Hoffmann-La Roche
-   GlaxoSmithKline (GSK)
-   Sun Pharma
-   Amgen Inc.
-   Rhythm Pharmaceuticals
-   Currax Holdings USA LLC
-   Boehringer Ingelheim
-   Vivus Inc.
-   Gelesis

**Key Topics Covered:**

**Executive Summary**

**1\. Product Definition**  
1.1 Inclusion and Exclusion

**2\. Market Scope**  
2.1 Scope of Work  
2.2 Key Questions Answered in the Report

**3\. Research Methodology**  
3.1 Data Sources  
3.1.1 Primary Data Sources  
3.1.2 Secondary Data Sources  
3.2 Market Estimation Model  
3.2.1 Assumptions Limitations

**4\. Global Weight Loss Drugs Market: Overview**  
4.1 Key Trends  
4.2 Pipeline Analysis  
4.3 Patent Analysis  
4.4 Regulatory Framework

**5\. Global Weight Loss Drugs Market: Market Dynamics**  
5.1 Impact Analysis  
5.2 Market Drivers  
5.3 Market Restraints  
5.4 Market Opportunities

**6\. Global Weight Loss Drugs Market (by Type), ($Million)**  
6.1 Prescription Weight Loss Drugs  
6.2 Over the Counter (OTC) Weight Loss Drugs

**7\. Global Weight Loss Drugs Market (by Mechanism of Action)**  
7.1 Appetite Suppressants  
7.2 Metabolic Boosters  
7.3 Fat Absorption Inhibitors

**8\. Global Weight Loss Drugs Market (by Route of Administration)**  
8.1 Oral  
8.2 Injectable

**9\. Global Weight Loss Drugs Market (by Distribution Channel)**  
9.1 Retail Pharmacies  
9.2 Online Pharmacies

**10\. Global Weight Loss Market (by Region), Value ($Million)**  
10.1 North America Weight Loss Drugs Market  
10.1.1 Market Dynamics  
10.1.2 Market Size and Forecast  
10.1.2.1 U.S.  
10.1.2.2 Canada  
10.2 Europe Weight Loss Drugs Market  
10.2.1 Market Dynamics  
10.2.2 Market Sizing and Forecast  
10.2.2.1 Germany  
10.2.2.2 U.K.  
10.2.2.3 France  
10.2.2.4 Rest-of-Europe  
10.3 Asia-Pacific Weight Loss Drugs Market  
10.3.1 Market Dynamics  
10.3.2 Market Size and Forecast  
10.3.2.1 China  
10.3.2.2 Japan  
10.3.2.3 India  
10.3.2.4 Rest-of Asia-Pacific  
10.4 Rest-of-the-World Weight Loss Drugs Market  
10.4.1 Market Dynamics  
10.4.2 Market Size and Forecast

**11\. Global Weight Loss Drugs Market: Competitive Landscape**  
11.1 Key Strategies and Development  
11.1.1 New Offerings  
11.1.2 Regulatory Approvals  
11.1.3 Mergers and Acquisitions  
11.1.4 Partnerships, Alliances, and Business Expansions  
11.1.5 Funding Activities  
11.2 Company Profiles  
11.2.1 Company Overview  
11.2.2 Product Portfolio/Offering  
11.2.3 Key Competitors  
11.2.4 Target Customers/End Users  
11.2.5 Analyst View

For more information about this report visit https://www.researchandmarkets.com/r/svnc48

**About ResearchAndMarkets.com**  
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

### Related Stocks

- [LLY.US - 礼来](https://longbridge.com/zh-CN/quote/LLY.US.md)
- [NVO.US - 诺和诺德公司](https://longbridge.com/zh-CN/quote/NVO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Novo Nordisk: Will Have Replacements for Ozempic and Wegovy Ready When Patents Expire - Berlingske | Danish pharmaceutical company Novo Nordisk plans to have replacement drugs ready for Ozempic and Wegovy when their paten | [Link](https://longbridge.com/zh-CN/news/276314777.md) |
| Novo Nordisk Aims To Start Selling Its Weight-Loss Blockbuster Wegovy In Vials - Bloomberg News | NOVO NORDISK AIMS TO START SELLING ITS WEIGHT-LOSS BLOCKBUSTER WEGOVY IN VIALS - BLOOMBERG NEWS | [Link](https://longbridge.com/zh-CN/news/275654518.md) |
| Eli Lilly (LLY) Builds $1.5 Billion Inventory of Weight-Loss Pill | Eli Lilly (LLY) has prepared a $1.5 billion inventory of its new weight-loss pill, Orforglipron, ahead of its anticipate | [Link](https://longbridge.com/zh-CN/news/276070062.md) |
| Puzo Michael J Has $320,000 Stock Position in Novo Nordisk A/S $NVO | Puzo Michael J significantly reduced its stake in Novo Nordisk A/S (NYSE:NVO) by 86.9% in Q3, now holding 5,775 shares v | [Link](https://longbridge.com/zh-CN/news/276447697.md) |
| Novo Nordisk Proposes Two Additional New Board Appointments | Danish pharmaceutical company Novo Nordisk is proposing three new appointments to its board of directors for the annual  | [Link](https://longbridge.com/zh-CN/news/276442777.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。
